E-resources
-
Parikh, Aparna R; Van Seventer, Emily E; Siravegna, Giulia; Hartwig, Anna V; Jaimovich, Ariel; He, Yupeng; Kanter, Katie; Fish, Madeleine G; Fosbenner, Kathryn D; Miao, Benchun; Phillips, Susannah; Carmichael, John H; Sharma, Nihaarika; Jarnagin, Joy; Baiev, Islam; Shah, Yojan S; Fetter, Isobel J; Shahzade, Heather A; Allen, Jill N; Blaszkowsky, Lawrence S; Clark, Jeffrey W; Dubois, Jon S; Franses, Joseph W; Giantonio, Bruce J; Goyal, Lipika; Klempner, Samuel J; Nipp, Ryan D; Roeland, Eric J; Ryan, David P; Weekes, Colin D; Wo, Jennifer Y; Hong, Theodore S; Bordeianou, Liliana; Ferrone, Cristina R; Qadan, Motaz; Kunitake, Hiroko; Berger, David; Ricciardi, Rocco; Cusack, James C; Raymond, Victoria M; Talasaz, AmirAli; Boland, Genevieve M; Corcoran, Ryan B
Clinical cancer research, 10/2021, Volume: 27, Issue: 20Journal Article
Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will ultimately recur. Most ctDNA MRD assays require tumor sequencing to identify tumor-derived mutations to facilitate ctDNA detection, requiring tumor and blood. We evaluated a plasma-only ctDNA assay integrating genomic and epigenomic cancer signatures to enable tumor-uninformed MRD detection. A total of 252 prospective serial plasma specimens from 103 patients with colorectal cancer undergoing curative-intent surgery were analyzed and correlated with recurrence. Of 103 patients, 84 stage I (9.5%), II (23.8%), III (47.6%), IV (19%) had evaluable plasma drawn after completion of definitive therapy, defined as surgery only ( = 39) or completion of adjuvant therapy ( = 45). In "landmark" plasma drawn 1-month (median, 31.5 days) after definitive therapy and >1 year follow-up, 15 patients had detectable ctDNA, and all 15 recurred positive predictive value (PPV), 100%; HR, 11.28 ( < 0.0001). Of 49 patients without detectable ctDNA at the landmark timepoint, 12 (24.5%) recurred. Landmark recurrence sensitivity and specificity were 55.6% and 100%. Incorporating serial longitudinal and surveillance (drawn within 4 months of recurrence) samples, sensitivity improved to 69% and 91%. Integrating epigenomic signatures increased sensitivity by 25%-36% versus genomic alterations alone. Notably, standard serum carcinoembryonic antigen levels did not predict recurrence HR, 1.84 ( = 0.18); PPV = 53.9%. Plasma-only MRD detection demonstrated favorable sensitivity and specificity for recurrence, comparable with tumor-informed approaches. Integrating analysis of epigenomic and genomic alterations enhanced sensitivity. These findings support the potential clinical utility of plasma-only ctDNA MRD detection. .
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.